We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Bayer AG | TG:BAYN | Tradegate | Ordinary Share |
Price Change | % Change | Share Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|
0.50 | 1.85% | 27.475 | 404,068 | 22:50:04 |
Bid Price | Offer Price | High Price | Low Price | Open Price | |
---|---|---|---|---|---|
27.375 | 27.57 | 27.61 | 26.94 | 26.945 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Chems, Allied Pds-whsl, Nec | 47.64B | -2.94B | -2.9936 | -9.01 | 26.5B |
Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
---|---|---|---|---|
20:59:17 | 80 | 27.375 | EUR |
Date | Time | Source | Headline |
---|---|---|---|
22/1/2024 | 14:26 | DJN | Bayer Names Nelson Ambrogio as New Head of Radiology Business |
08/1/2024 | 08:05 | DJN | Bayer's Menopause Drug Elinzanetant Met Primary Endpoints in Phase 3.. |
19/12/2023 | 10:12 | DJN | Bayer's Monsanto Ordered to Pay $857 Million Over Chemicals in Washington.. |
20/11/2023 | 15:43 | DJN | Trending: Bayer Shares Tank After Key Clinical Trial Halted Early, Roundup.. |
20/11/2023 | 10:20 | DJN | Bayer Shares Tumble After Clinical Trial Failure, Roundup Case Loss |
20/11/2023 | 07:22 | DJN | Bayer Stops Late-Stage Study for Stroke Prevention Due to Lack of Efficacy |
13/11/2023 | 15:58 | DJN | Bayer Pulling Lymphoma Drug Aliqopa From U.S. |
10/11/2023 | 15:00 | DJN | Bayer Gets CHMP Backing for Higher-Dose Eylea in Two Major Retinal Eye.. |
08/11/2023 | 10:32 | DJN | Bayer Weighs Structural Changes But Rules Out Three-Way Split -- 3rd Update |
08/11/2023 | 08:40 | DJN | Bayer Weighs Structural Changes But Rules Out Three-Way Split -- 2nd Update |
Bayer (BAYN) Share Charts1 Year Bayer Chart |
|
1 Month Bayer Chart |
Intraday Bayer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions